

JUN 10 1998

**510(k) PREMARKET NOTIFICATION
ACE® T Uptake Reagent**

K981375

SUMMARY OF SAFETY AND EFFECTIVENESS

In lieu of a 510(k) statement under 513(i) of the Act, this Summary of Safety and Effectiveness is provided as a 510(k) summary for disclosure to any other persons/companies without specific written authorization from Schiapparelli Biosystems, Inc.

Submitter

Schiapparelli Biosystems, Inc.
368 Passaic Avenue
Fairfield, NJ 07004
Phone: (973) 882-8630

Contact Person

Steven Dalessio
Manager, Quality Assurance/Regulatory Affairs
Phone: (973) 882-8630

Device Names

Proprietary Name: ACE® T Uptake Reagent
Common Name: Enzyme immunoassay for T Uptake
Classification Name: T Uptake test

Predicate Device: Diagnostic Reagents, Inc. (DRI) - T Uptake Reagent
[510(k) Number K951586]

Device Description

The ACE T Uptake Regent contains two reagents, and Antibody/Substrate reagent and an Enzyme Conjugate reagent. The assay uses a mixture of enzyme glucose-6-phosphate dehydrogenase conjugated thyroxine (G6PD-T4) and a known amount of exogeneous T4 which is allowed to bind to the thyroxine-binding proteins in the sample. A sample with increased levels of unsaturated thyroxine-binding sites, the exogeneous T4 will bind leaving G6PD-T4 conjugate free. On addition of an anti-thyroxine antibody, the G6PD-T4 conjugate is bound by the antibody and the enzyme activity is inhibited. Conversely, a sample with decreased levels of unsaturated thyroxine-binding sites will leave most exogeneous T4 unbound. Upon addition of anti-T4 antibody, the unbound exogeneous T4 will inhibit the anti-T4 binding to G6PD-T4 conjugate and produce a high G6PD enzyme activity. This phenomenon creates a relationship between unsaturated thyroxine-binding sites concentration (T Uptake) and the enzyme activity. The enzyme G6PD activity is determined bichromatically on the ACE® at 340/505 nm by measuring its ability to convert NAD⁺ to NADH.

Intended Use of the Device

ACE® T Uptake Reagent is intended for use in the quantitative determination of unsaturated binding sites on the thyroid-binding proteins in human serum.

9

**510(k) PREMARKET NOTIFICATION
ACE® T Uptake Reagent**

SUMMARY OF SAFETY AND EFFECTIVENESS

COMPARATIVE FEATURES OF PREDICATE AND PROPOSED DEVICES

PARAMETER	PREDICATE DEVICE	PROPOSED DEVICE
Trade Name	DRI T Uptake Enzyme Immunoassay	ACE® T Uptake Reagent
Reference No.	K951586	TBD
Analyte	T Uptake	T Uptake
Intended Use	Quantitative determination of unsaturated binding sites on the thyroid-binding proteins	Quantitative determination of unsaturated binding sites on the thyroid-binding proteins
Methodology	Enzyme immunoassay	Enzyme immunoassay
Reagents		
Reagent 1 Volume	Liquid; Enzyme conjugate 210 µL	Liquid; Enzyme conjugate 210 µL
Reagent 2 Volume	Liquid; Antibody/Substrate 70 µL	Liquid; Antibody/Substrate 70 µL
Specimen Type	Serum and plasma	Serum
Volume	9 µL	9 µL
Assay System		
Reagent 1 + Sample	Incubate 288 sec	Incubate 240 sec
Reagent 2	Read 120 to 192 sec (12 sec intervals)	Read 63 and 273 sec
Temperature	37 °C	37 °C
Detection Method		
Type	Spectrophotometric	Spectrophotometric
Wavelength, nm	Bichromatic: 340/415	Bichromatic: 340/505

**510(k) PREMARKET NOTIFICATION
ACE® T Uptake Reagent**

SUMMARY OF SAFETY AND EFFECTIVENESS

PERFORMANCE ASSESSMENT

Non-clinical test results submitted in the premarket notification include within-run and between-run precision and method correlation. Following is a data summary.

PARAMETER	PREDICATE DEVICE	PROPOSED DEVICE
Performance Summary		
Assay Range	15% to 50%	15% to 50%
Precision		
Within Run	3.6 %CV	3.7 %CV
Between Run	3.3 %CV	4.1 %CV
Correlation vs	Commercial EIA assay for FTI	Hitachi 717 Assay for T Uptake
Slope	0.92	1.085
Intercept	0.69	-3.460
r	0.9	0.935
N	110	50

Based on these data, the Schiapparelli Biosystems ACE® T Uptake Reagent is substantially equivalent to the predicate device (Diagnostic Reagents, Inc. T Uptake Enzyme Immunoassay). On this basis, the reagent is determined to be safe and effective for its intended use. Performance details are included in the reagent product labeling.



JUN 10 1998

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

Steven Dalessio
• Manager, Quality Assurance/Regulatory Affairs
Schiapparelli Biosystems, Inc.
368 Passaic Avenue
Fairfield, New Jersey 07004

Re: K981375
ACE® T Uptake Reagent
Regulatory Class: II
Product Code: KHQ, JIS
Dated: April 15, 1998
Received: April 16, 1998

Dear Mr. Dalessio:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your pre-market notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsmamain.html>".

Sincerely yours,



Steven I. Gutman, M.D., M.B.A.
Director
Division of Clinical
Laboratory Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K981375

Device Name: ACE[®] T Uptake Reagent

Indications For Use:

ACE[®] T Uptake Reagent is used in the diagnosis and treatment of thyroid disorders. It is intended for the quantitative determination of unsaturated binding sites on the thyroid-binding proteins in serum using the ACE clinical chemistry analyzer.



510(k) Number: K 981375 ^{vices}

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)